CCEA approves foreign investments worth Rs 2,165 crore in Aurobindo Pharma

08 Apr 2015 Evaluate

The Cabinet Committee on Economic Affairs (CCEA) has approved foreign investments in Aurobindo Pharma. The approval has been given for Qualified Institutional Buyers (QIBs) to infuse fresh equity of up to 7% amounting to about Rs 2,165 crore into the company. The existing FII shareholding is 27.32% in the company.

This will enable the company to expand its operations in the areas of anti infective, cardiovascular and central nervous system related ingredients. The company employs more than 9500 professionals from 26 countries.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.


Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×